RE: .15 Jun 2021 12:06
Big,
Is your contribution here just sarcasm or actually have an educated guess? Everyone has to make their own minds re their risk appetite, however listening people's alternative views are extremely important as they may consider criteria's I may have missed.
I am not sure how much analysis you do, but you seem to miss 3 fundamental factors, the correlation with the US market cash inflow outflow on LSE which is much higher than I originally assumed and the fact that even the analysts the most of the time disagree about the SP directions. On the US stocks I have 5 different analysts I follow on each SP and they couldn't be more different in their views.
Third, we trade in a constant changing environment influenced on one side by the company fundamentals on the other of the cash flow movement "rotation" which I saw affecting even major SPs like GSK, AZN, BAE, EXP ca 20%-25%. What one may said a month ago may be invalid later given that Biden fundamentally changed the US energy strategy and the environmental groups started to take Large energy corporates to court; no one believed that RDS will loose the Dutch court case.
Maybe you have to start to look to the arguments behind an opinion at that point in time; sarcasm doesn't take us anywhere, out of your last 6 posts I couldn't make any sense of what you tried to achieve beyond ranting which has its own benefit if you feel better after.
My only worry is not that Dan may not succeed, but that the investors consider MTRO a cash/ value trap, meaning that it is not enough spike upside in a relatively short time. I did a test in the last few days with SSP which in spite having a worse financial position than MTRO it raised 8% in just 10 days because there s enough trading liquidity and volatility.
Since I started posting here, I downloaded all the MTRO transactions every single day and I can't see any operational news to take it beyond 10% up IMO.
As someone posted here, a major impact would be concept/ strategic redesign of the High street presence; if any ideas, write to Dan. Some 7 of us we wrote to EW on GSK, not that she read it, but her team may have redirected it to the right department.
I will definitely write to him to suggest a change the ratesetter front end as it is old fashioned, asking for personal details prior giving an indicative offer; this is considered a significant acquisition deterrent.
GLA